November 05, 2026

To, The Listing Department, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400001 **Scrip code: 544889**	To, The Listing Department National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai – 400051 **Symbol: SYMBIOTEC**

Sub.: Outcome of the Board Meeting of the Company.

Ref.: 1. Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations");
2. Our intimation dated October 28, 2026

Dear Sir / Madam,

With reference to the captioned subject, this is to inform you that the Board of Directors of the Company at its meeting held today i.e., Thursday, November 05, 2026, have inter alia considered and approved the Unaudited Standalone & Consolidated Financial Results for the quarter and half year ended September 30, 2026 ("unaudited Financial Results").

Enclosed are the Unaudited Financial Results along with Limited Review Reports for your records. (Pursuant to Regulation 47 of the SEBI Listing Regulations, extract of these results will be published in newspapers).

The meeting commenced at 04:30 p.m. and concluded at 5.30 p.m.

The Trading Window for dealing in Company's securities shall remain closed until 48 hours from this announcement.

The above information is being made available on website of the Company i.e. https://investor.symbiotec.com/financials?tab=results

Thanking You.
Sincerely,

For **Symbiotec Pharmalab Limited**

SALIL JAIN
Digitally signed by SALIL JAIN
Date: 2026.11.05 19:24:46 +05'30'

Salil Jain
Company Secretary and Compliance Officer
Membership No. A41610

Encl: As above

Registered Office & Works:
Symbiotec Pharmalab Limited
(Formerly known as Symbiotec Pharmalab Pvt. Ltd.)
385/2, Pigdamber, Rau, Mhow, Indore - 453331, Madhya Pradesh, India
Tel. No.: +91-731-6676405-406 Fax: +91-731-4201222,
Email ID : symbiotec@symbiotec.com, **Website** : www.symbiotec.com
CIN: U24232MP2002PLC015293

S R B C & CO LLP
Chartered Accountants

12th Floor, The Ruby
29 Senapati Bapat Marg
Dadar (West)
Mumbai - 400 028, India
Tel: +91 22 6819 8000

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Symbiotec Pharmalab Limited (formerly known as Symbiotec Pharmalab Private Limited)

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Symbiotec Pharmalab Limited (formerly known as Symbiotec Pharmalab Private Limited) ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together, referred to as 'the Group'), for the quarter ended September 30, 2026 and year to date from April 01, 2026 to September 30, 2026 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the financial results of the subsidiaries. For list of entities, refer to Annexure A below.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS'), specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of four subsidiaries, whose interim financial results and other financial information includes total assets of Rs 172.77 million as at September 30, 2026, total revenue of Rs 1.69 million and Rs 10.17 million, total net loss after tax of Rs 0.18 million and 3.90 million, total comprehensive loss of Rs. 1.38 million and 3.57 million for the quarter ended September 30, 2026 and half year ended on that date respectively and net cash inflows of Rs 7.91 million for the period from April 01, 2026 to September 30, 2026, as considered in the statement.

   The unaudited interim financial information/financial results and other unaudited financial information of these subsidiaries have not been reviewed by any auditor and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, this interim financial results/financial information are not material to the Group.

   Our conclusion on the Statement in respect of matters stated in para above is not modified with respect to the financial results/financial information certified by the Management.

7. The Ind AS financial information of the Group for the quarter ended September 30, 2025, and half year ended September 30, 2025, included in these unaudited consolidated Ind AS financial results have not been subject to an audit or review by us or any other auditor and are approved by the Board of Directors of the Holding Company.

For S R B C & CO LLP
Chartered Accountants
ICAI Firm registration number: 324982E/E300003

Anilkumar Chandubhai Jobanputra

Digitally signed by Anilkumar Chandubhai Jobanputra
DN: cn=Anilkumar Chandubhai Jobanputra, c=IN, o=Personal
Date: 2026.11.05 19:04:01 +05'30'

per Anil Jobanputra
Partner
Membership No.: 110759

UDIN: 26110759MTOJQS3126

Place: Mumbai
Date: November 05, 2026

Annexure A

(Referred to in paragraph 4 of our report of even date)

List of entities included in these results

Sr. No.	Name of entity	Relationship
1	Symbiotec Pharamalab Limited (SPL)	Holding Company
2	Knovea Pharmaceuticals Private Limited (KPPL)	Subsidiary of SPL
3	Symbiotec Zenfold Private Limited (SZPL)	Subsidiary of SPL
4	Navisci Pte Limited (NPL)	Subsidiary of SPL
5	Xinjiang Symbiotec Biotechnology Limited (XSBL)	Subsidiary of SPL
6	Symbiotec Biologics Private Limited (SBPL)	Subsidiary of SPL
7	Xenamed Corp.	Subsidiary of NPL

Symbiotec Pharmalab Limited

Corporate Identity Number (CIN):U24232MP2002PLC015293

Regd. Office:385/2, Pigdamber, Rau, Mhow,Indore – 453331, Madhya Pradesh, India

Email: investorrelations@symbiotec.com Website: https://symbiotec.com

Statement of unaudited consolidated financial results for the Quarter ended and Half year ended September 30,2026

(Rs. in Million)

Particulars	Quarter ended			Half Year ended		Year ended
	September 30,2026 (Unaudited)	June 30,2026 (Unaudited) (Refer Note 4)	September 30,2025 (Refer Note 3)	September 30,2026 (Unaudited)	September 30,2025 (Refer Note 3)	March 31,2026 (Audited) (Refer Note 4)
Income						
Revenue from operations	2,799.28	2,181.50	1,955.15	4,980.78	3,986.87	8,691.49
Other income	1.12	3.38	1.60	4.50	28.01	31.09
Total income (A)	**2,800.40**	**2,184.88**	**1,956.75**	**4,985.28**	**4,014.88**	**8,722.58**
Expenses						
Cost of raw materials, packing material and consumables consumed	796.16	755.59	701.00	1,551.75	1,474.27	3,154.64
Employee benefit expenses	469.58	464.21	376.96	933.79	728.37	1,543.39
Finance costs	57.04	61.79	63.86	118.83	116.63	253.27
Depreciation and amortisation expense	218.74	218.24	105.88	436.98	210.96	532.83
Other expenses	618.44	509.73	374.35	1,128.17	701.73	1,614.89
Total expenses (B)	**2,159.96**	**2,009.56**	**1,622.05**	**4,169.52**	**3,231.96**	**7,099.02**
Profit before exceptional item and tax (C= (A-B))	**640.44**	**175.32**	**334.70**	**815.76**	**782.92**	**1,623.56**
Exceptional item (D)						
Impact of New wages code on Gratuity and Leave encashment	-	-	-	-	-	89.93
Profit before tax (E=(C-D))	**640.44**	**175.32**	**334.70**	**815.76**	**782.92**	**1,533.63**
Income Tax expense						
Current tax Charge/(Credit)	169.42	160.20	145.06	329.62	305.17	593.75
Adjustment of tax relating to earlier period/year Charge/(Credit)	-	-	-	-	-	1.96
Deferred Tax Charge/(Credit)	(46.16)	(125.49)	(2.54)	(171.65)	(13.63)	(140.04)
Deferred Tax relating to Exceptional items Charge/(Credit)	-	-	-	-		(21.07)
Total Income tax expense/(credit) (F)	**123.26**	**34.71**	**142.52**	**157.97**	**291.54**	**434.60**
Net Profit for the period/year (G= (E-F))	**517.18**	**140.61**	**192.18**	**657.79**	**491.38**	**1,099.03**
Other comprehensive income, net of income tax						
Items that will be reclassified to profit and loss in subsequent period						
Exchange difference on translation of foreign operations	(1.24)	1.53	0.02	0.29	0.50	(8.10)
Items that will not be reclassified to profit and loss in subsequent period						
Re-measurements gains/ (losses) on defined benefit plans	10.77	(1.11)	0.74	9.66	(1.31)	(3.72)
Income tax effect on above	(2.66)	0.24	(0.16)	(2.42)	0.33	0.66
Total (H)	8.11	(0.87)	0.58	7.24	(0.98)	(3.06)
Total other comprehensive Income/(loss), net of income tax (I)	**6.87**	**0.66**	**0.60**	**7.53**	**(0.48)**	**(11.16)**
Total comprehensive income for the period/year (J)=(G+I)	**524.05**	**141.27**	**192.78**	**665.32**	**490.90**	**1,087.87**
Total comprehensive income for the period/year attributable to:						
Owners of the Parent Company	524.04	141.21	192.79	665.25	490.86	1,087.38
Non-controlling interests	0.01	0.06	(0.01)	0.07	0.04	0.49
Net Profit attributable to:						
Owners of the Parent Company	517.26	140.56	192.19	657.82	491.37	1,098.82
Non-controlling interests	(0.08)	0.05	(0.01)	(0.03)	0.01	0.21
Other comprehensive Income/(loss) attributable to:						
Owners of the Parent Company	6.78	0.65	0.59	7.43	(0.51)	(11.44)
Non-controlling interests	0.09	0.01	0.01	0.10	0.03	0.28
Paid-up equity share capital (Face value of Rs 2/- per share)	128.51	125.47	125.47	128.51	125.47	125.47
Other Equity						11,371.83
Earnings per share (of face value Rs. 2/- per share) [not annualised]						
Basic (in Rs.)	8.20	2.24	3.45	10.44	8.82	19.10
Diluted (in Rs.)	8.20	2.24	3.43	10.44	8.77	19.00

Symbiotec Pharmalab Limited
Corporate Identity Number (CIN):U24232MP2002PLC015293
Regd. Office:385/2, Pigdamber, Rau, Mhow,Indore – 453331, Madhya Pradesh, India
Email: investorrelations@symbiotec.com Website: https://symbiotec.com

Unaudited Consolidated Statement of Assets and Liabilities

(Rs. in Million)

Particulars	As at September 30, 2026	As at March 31, 2026
	Unaudited	Audited
Assets		
Non-current assets		
Property, plant and equipment	**10,549.90**	10,843.87
Capital work-in-progress	**1,380.90**	644.81
Investment properties	**356.74**	359.38
Financial assets		
(i) Investments	**44.84**	44.84
(ii) Other financial assets	**201.28**	89.43
Deferred tax assets (net)	**111.05**	-
Income tax assets (net)	**0.34**	0.21
Other non-current assets	**1,272.18**	969.94
Total non-current assets (A)	**13,917.23**	12,952.48
Current assets		
Inventories	**3,033.58**	2,368.81
Financial assets		
(i) Trade receivables	**2,682.77**	1,975.98
(ii) Cash and cash equivalents	**216.56**	100.40
(iii) Bank Balances other than cash and cash equivalents	**1.10**	0.85
(iv) Other financial assets	**267.86**	272.34
Other current assets	**320.05**	137.06
Total current assets (B)	**6,521.92**	4,855.44
Total assets (C)=(A+B)	**20,439.15**	17,807.92
Equity and Liabilities		
Equity		
Equity share capital	**128.51**	125.47
Other equity	**13,480.90**	11,371.83
Equity attributable to the equity shareholders of the parent company	**13,609.41**	11,497.30
Non Controlling Interest	**(1.33)**	(1.40)
Total equity (D)	**13,608.08**	11,495.90
Liabilities		
Non-current liabilities		
Financial Liabilities		
(i) Borrowings	**1,622.28**	684.13
(ii) Lease liabilities	**22.34**	20.51
(iii) Other financial liabilities	**171.07**	57.87
Provisions	**217.41**	215.73
Deferred tax liabilities (net)	**-**	58.13
Total non-current liabilities (E)	**2,033.10**	1,036.37
Current liabilities		
Financial liabilities		
(i) Borrowings	**1,709.16**	3,195.01
(ii) Lease liabilities	**5.32**	10.25
(iii) Trade payables		
Total outstanding dues of micro enterprises and small enterprises	**117.64**	50.81
Total outstanding dues of creditors other than micro enterprises and small enterprises	**1,609.13**	1,332.46
(iv) Other financial liabilities	**752.72**	344.43
Other current liabilities	**400.41**	197.37
Provisions	**67.25**	65.86
Current tax liabilities (net)	**136.34**	79.46
Total current liabilities (F)	**4,797.97**	5,275.65
Total liabilities (G)=(E+F)	**6,831.07**	6,312.02
Total equity and liabilities (H)= (D+G)	**20,439.15**	17,807.92

Symbiotec Pharmalab Limited
Corporate Identity Number (CIN):U24232MP2002PLC015293
Regd. Office:385/2, Pigdamber, Rau, Mhow,Indore – 453331, Madhya Pradesh, India
Email: investorrelations@symbiotec.com Website: https://symbiotec.com

Unaudited Consolidated statement of cash flows for the Half year ended September 30,2026

Particulars		Half year ended September 30, 2026 unaudited	Half year ended September 30, 2025 (Refer Note 3)
		Rs. in Million	Rs. in Million
Cash flow from operating activities			
Profit before tax		**815.76**	782.92
Adjustment to reconcile profit before tax to net cash flows:			
Depreciation and amortisation		**436.98**	210.96
Foreign exchange differences (gain)/loss (net)		**(14.32)**	(15.79)
Loss/(Gain) on disposal of property, plant and equipment (net)		**7.94**	(3.84)
Finance Cost		**118.83**	116.63
Interest income classified as Investing cash flows		**(1.13)**	(0.66)
Share based payment expense		**-**	74.76
Operating profit before working capital changes		**1,364.06**	1,164.98
Movement in Working Capital			
(Increase) in trade and other receivables and prepayments		**(1,114.86)**	(246.93)
(Increase) in inventories		**(664.77)**	(0.34)
Increase in trade payables and other payables		**1,135.10**	557.97
Increase in provisions		**12.73**	11.37
Cash generated from operations		**732.26**	1,487.05
Income taxes paid (net of refunds)		**(272.88)**	(230.35)
Net cash flows generated from operating activities	**(A)**	**459.38**	1,256.70
Cash Flow from investing activities			
Purchase of Property, plant and equipment including captial work in progress and capital advances		**(1,135.37)**	(1,101.92)
Proceeds from sale of property, plant and equipment		**2.96**	16.85
Fixed deposit / Margin money placed		**(0.59)**	-
Fixed deposit / Margin money matured		**10.26**	-
Interest received		**1.13**	0.70
Net cash flow used in investing activities	**(B)**	**(1,121.61)**	(1,084.37)
Cash flow from financing activities			
Proceeds from Fresh issue of Equity shares		**3.04**	-
Securities premium on fresh issue of Equity shares		**1,496.96**	-
Share issue expenses		**(53.15)**	-
Proceeds/(repayment) from short-term borrowings (net)		**(1,459.12)**	(170.29)
Proceeds from long-term borrowings		**1,069.95**	180.29
Repayment of long-term borrowings		**(159.99)**	(289.99)
Payment of Lease Liabilities		**(4.48)**	(6.09)
Interest paid on Lease liabilities		**(1.52)**	(1.91)
Finance cost excluding (Interest paid on Lease liabilities) paid		**(113.30)**	(118.29)
Net cash flow generated from financing activities	**(C)**	**778.39**	(406.28)
Net increase/(decrease) in cash and cash equivalents	**(A+B+C)**	116.16	(233.95)
Cash and cash equivalents at the beginning of the period		**100.40**	263.90
Cash and cash equivalents at the end of the period		**216.56**	29.95

Symbiotec Pharmalab Limited

Corporate Identity Number (CIN):U24232MP2002PLC015293

Regd. Office:385/2, Pigdamber, Rau, Mhow,Indore – 453331, Madhya Pradesh, India

Email: investorrelations@symbiotec.com Website: https://symbiotec.com

Statement of unaudited consolidated financial results for the quarter ended and half year ended September 30,2026

Notes:

1. The Unaudited Consolidated Financial Results ("Statements") of the Symbiotec Pharmalab Limited ("Holding Company") and its subsidiaries (together referred to as the 'Group') for the quarter ended and half year ended on September 30, 2026, has been reviewed by the Audit Committee and thereafter approved by the Board of Directors at its meeting held on November 5, 2026. The statutory auditors have carried out a limited review of these Statements and issued unmodified report thereon.

2. These Statements has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, (Ind AS 34) Interim Financial Reporting prescribed under section 133 of Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

3. The Unaudited Consolidated financial results for the quarter ended and half year ended September 30, 2025, are presented based on the information compiled by management of the Holding Company and have not been subjected to review or audit by the statutory auditors. However, the management has prepared the results for the said period applying consistent accounting policies and has exercised necessary due diligence to ensure the said figures provide a true and fair view of the Group's affairs.

4. The figures of the quarter ended June 30, 2026, have been extracted from the unaudited financial results of the Group and the figures for the year ended March 31, 2026, have been extracted from the audited financial statements of the Group.

5. During the quarter ended September 30, 2026, the Holding Company had completed its Initial Public Offering ("IPO") of 1,77,86,442 nos. of equity shares of face value of Rs. 2 each at an issue price of Rs. 988 per share (including a share premium of Rs. 986 per share). A discount of Rs. 90 was offered to eligible employees bidding in the employee's reservation portion of 33,407 nos. of equity shares. The issue comprised of 15,21,261 nos. of equity shares offered as fresh issue aggregating to Rs. 1,500.00 million and 1,62,65,181 nos. of equity shares offered as offer for sale by selling shareholders aggregating to Rs. 16,070.00 million. Pursuant to IPO, the equity shares of the Holding Company were listed on National Stock Exchange of India Limited ("NSE") and BSE Limited ("BSE") on September 1, 2026.

   Consequent to allotment of fresh issue, the paid up equity share capital of the Holding Company has increased from Rs. 125.47 million consisting of 62,734,851 equity shares of Rs. 2 each to Rs. 128.51 million consisting of 64,256,112 equity shares of Rs. 2 each.

   The Company received net proceeds of Rs. 1,420.25 million (net of IPO expenses of Rs. 79.75 million). The utilisation of net proceeds is summarised below:

Symbiotec Pharmalab Limited
Corporate Identity Number (CIN):U24232MP2002PLC015293
Regd. Office:385/2, Pigdamber, Rau, Mhow,Indore – 453331, Madhya Pradesh, India
Email: investorrelations@symbiotec.com Website: https://symbiotec.com

Statement of unaudited consolidated financial results for the quarter ended and half year ended September 30,2026

(Amount in Rs. millions)

Particulars	Net proceeds to be utilised as per prospectus	Utilisation of net proceeds upto September 30, 2026	Unutilised net proceeds upto September 30, 2026
Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by our Company	1125.25	1125.00	0.25**
General corporate purposes	295.00	295.00*	-
Total	**1,420.25**	**1,420.00**	**0.25**

*Comprises of certain borrowings prepaid/repaid of Rs. 295 million from the general corporate purposes pool.
**Out of the net IPO proceeds which were unutilised as at September 30, 2026, Rs. 0.25 million is held in Monitoring account.

6. The Group's business segment consists of a single segment of "Manufacturing and Selling of Pharmaceuticals products and services" as per the requirement of Indian Accounting Standard (Ind AS) 108 "Operating Segment". Accordingly, no separate segment information is provided.

7. Exceptional item for the year ended March 31, 2026, relates to Impact of new wage code on gratuity and leave encashment, resulting in an expense of Rs. 89.93 million.

8. These unaudited consolidated financial results of the Group for the quarter ended and half year ended September 30, 2026, are available on the BSE Limited website (URL: www.bseindia.com), National Stock Exchange of India Limited (URL: www.nseindia.com), and on the Company's website (URL: www.symbiotec.com).

For and on behalf of the Board of Directors of
Symbiotec Pharmalab Limited
CIN : U24232MP2002PLC015293

ANIL SATWANI
Digitally signed by ANIL SATWANI
Date: 2026.11.05 18:58:08 +05'30'

Anil Satwani
Managing Director
Place: Indore
Date: November 05,2026

S R B C & CO LLP
Chartered Accountants

12th Floor, The Ruby
29 Senapati Bapat Marg
Dadar (West)
Mumbai - 400 028, India
Tel: +91 22 6819 8000

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Symbiotec Pharmalab Limited (formerly known as Symbiotec Pharmalab Private Limited)

1. We have reviewed the accompanying statement of unaudited standalone financial results of Symbiotec Pharmalab Limited (formerly known as Symbiotec Pharmalab Private Limited) ('the Company') for the quarter ended September 30, 2026 and year to date from April 01, 2026 to September 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. The Company's Management is responsible for the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with the recognition and measurement principles laid down in aforesaid Indian Accounting Standard 34 ('Ind AS'), specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. The Ind AS financial information of the Company for the quarter ended September 30, 2025, and half year ended September 30, 2025, included in these unaudited standalone Ind AS financial results have not been subject to an audit or review by us or any other auditor and are approved by the Board of Directors of the Company.

For S R B C & CO LLP
Chartered Accountants
ICAI Firm registration number: 324982E/E300003

Anilkumar Chandubhai Jobanputra

Digitally signed by Anilkumar Chandubhai Jobanputra
DN: cn=Anilkumar Chandubhai Jobanputra, c=IN, o=Personal
Date: 2026.11.05 19:04:31 +05'30'

per Anil Jobanputra
Partner
Membership No.: 110759

UDIN: 26110759AQETRJ3823

Place: Mumbai
Date: November 05, 2026

Symbiotec Pharmalab Limited

Corporate Identity Number (CIN):U24232MP2002PLC015293

Regd. Office:385/2, Pigdamber, Rau, Mhow,Indore – 453331, Madhya Pradesh, India

Email: investorrelations@symbiotec.com Website: https://symbiotec.com

Statement of unaudited standalone financial results for the Quarter ended and Half year ended September 30,2026

(Rs. in Million)

Particulars	Quarter ended			Half Year ended		Year ended
	September 30,2026 (Unaudited)	June 30,2026 (Unaudited) (Refer Note 4)	September 30,2025 (Refer Note 3)	September 30,2026 (Unaudited)	September 30,2025 (Refer Note 3)	March 31,2026 (Audited) (Refer Note 4)
Income						
Revenue from operations	2,200.22	2,108.43	2,019.18	4,308.65	4,061.80	8,451.65
Other income	202.26	195.47	120.49	397.73	235.23	567.25
Total income (A)	**2,402.48**	**2,303.90**	**2,139.67**	**4,706.38**	**4,297.03**	**9,018.90**
Expenses						
Cost of raw materials, packing material and consumables consumed	783.54	783.97	694.26	1,567.51	1,468.24	3,193.79
Employee benefit expenses	360.43	352.20	368.31	712.63	707.50	1,422.37
Finance costs	49.67	56.20	63.37	105.87	114.51	238.00
Depreciation and amortisation expense	100.31	101.47	93.77	201.78	186.76	393.66
Other expenses	456.44	379.86	351.48	836.30	657.47	1,429.21
Total expenses (B)	**1,750.39**	**1,673.70**	**1,571.19**	**3,424.09**	**3,134.48**	**6,677.03**
Profit before exceptional items and tax (C= (A-B))	**652.09**	**630.20**	**568.48**	**1,282.29**	**1,162.55**	**2,341.87**
Exceptional Items :						
Provision for Impairment of investment and loans in/given to subsidiary	-	-	-	-	-	528.13
Impact of New wages code on Gratuity and Leave encashment	-	-	-	-	-	83.21
Total (D)	**-**	**-**	**-**	**-**	**-**	**611.34**
Profit/(Loss) before tax (E=(C-D))	**652.09**	**630.20**	**568.48**	**1,282.29**	**1,162.55**	**1,730.53**
Income Tax expense						
Current tax Charge/(Credit)	169.42	160.20	145.06	329.62	305.17	593.75
Adjustment of tax relating to earlier period/year Charge/(Credit)	-	-	-	-	-	1.96
Deferred Tax Charge/(Credit)	(2.71)	(0.08)	(2.54)	(2.79)	(13.63)	(2.50)
Deferred Tax relating to Exceptional items Charge/(Credit)	-	-	-	-	-	(20.94)
Total Income tax expense/(credit) (F)	**166.71**	**160.12**	**142.52**	**326.83**	**291.54**	**572.27**
Net Profit/(Loss) for the period/year (G=(E-F)	**485.38**	**470.08**	**425.96**	**955.46**	**871.01**	**1,158.26**
Other comprehensive income, net of income tax						
Items that will not be reclassified to profit and loss in subsequent period						
Re-measurements gains/ (losses) on defined benefit plans	10.10	(0.66)	0.63	9.44	(1.31)	(2.62)
Income tax effect on above	(2.55)	0.17	(0.16)	(2.38)	0.33	0.66
Total other comprehensive Income, net of income tax (H)	**7.55**	**(0.49)**	**0.47**	**7.06**	**(0.98)**	**(1.96)**
Total comprehensive income for the period/year (I)=(G+H)	**492.93**	**469.59**	**426.43**	**962.52**	**870.03**	**1,156.30**
Paid-up equity share capital (Face value of Rs 2/- per share)	128.51	125.47	125.47	128.51	125.47	125.47
Other Equity						12,418.11
Earnings per share (of face value Rs. 2/- per share) [not annualised]						
Basic (in Rs.)	7.68	7.49	7.65	15.17	15.65	20.13
Diluted (in Rs.)	7.68	7.49	7.61	15.17	15.56	20.03

Symbiotec Pharmalab Limited
Corporate Identity Number (CIN):U24232MP2002PLC015293
Regd. Office:385/2, Pigdamber, Rau, Mhow,Indore – 453331, Madhya Pradesh, India
Email: investorrelations@symbiotec.com Website: https://symbiotec.com

Unaudited Standalone Statement of Assets and Liabilities

(Rs. in Million)

Particulars	As at September 30, 2026	As at March 31, 2026
	Unaudited	Audited
Assets		
Non-current assets		
Property, plant and equipment	**3,632.07**	3,757.91
Capital work-in-progress	**79.11**	24.42
Financial assets		
(i) Investments	**111.07**	110.07
(ii) Other financial assets	**10,367.51**	9,271.15
Other non-current assets	**66.46**	35.58
Total non-current assets (A)	**14,256.22**	13,199.13
Current assets		
Inventories	**2,644.04**	2,147.67
Financial assets		
(i) Trade receivables	**1,874.52**	1,968.54
(ii) Cash and cash equivalents	**160.59**	50.39
(iii) Bank Balances other than cash and cash equivalents	**1.10**	0.85
(iv) Other financial assets	**265.77**	770.86
Other current assets	**255.57**	105.17
Total current assets (B)	**5,201.59**	5,043.48
Total assets (C)=(A+B)	**19,457.81**	18,242.61
Equity and Liabilities		
Equity		
Equity share capital	**128.51**	125.47
Other equity	**14,824.42**	12,418.11
Total equity (D)	**14,952.93**	12,543.58
Liabilities		
Non-current liabilities		
Financial Liabilities		
(i) Borrowings	**619.46**	632.33
(ii) Lease liabilities	**12.94**	11.34
(iii) Other financial liabilities	**171.07**	57.87
Provisions	**190.84**	192.61
Deferred tax liabilities (net)	**195.39**	195.81
Total non-current liabilities (E)	**1,189.70**	1,089.96
Current liabilities		
Financial liabilities		
(i) Borrowings	**1,297.70**	2,865.47
(ii) Lease liabilities	**4.65**	9.25
(iii) Trade payables		
Total outstanding dues of micro enterprises and small enterprises	**105.69**	36.83
Total outstanding dues of creditors other than micro enterprises and small enterprises	**1,486.43**	1,337.20
(iv) Other financial liabilities	**62.78**	79.26
Other current liabilities	**189.91**	170.36
Provisions	**62.20**	61.77
Current tax liabilities (net)	**105.82**	48.93
Total current liabilities (F)	**3,315.18**	4,609.07
Total liabilities (G)=(E+F)	**4,504.88**	5,699.03
Total equity and liabilities (H)=(D+G)	**19,457.81**	18,242.61

Symbiotec Pharmalab Limited
Corporate Identity Number (CIN):U24232MP2002PLC015293
Regd. Office:385/2, Pigdamber, Rau, Mhow,Indore – 453331, Madhya Pradesh, India
Email: investorrelations@symbiotec.com Website: https://symbiotec.com

Unaudited Standalone statement of cash flows for the Half year ended September 30,2026

Particulars		Half year ended September 30, 2026 unaudited	Half year ended September 30, 2025 (Refer Note 3)
		Rs. in Million	Rs. in Million
Cash flow from operating activities			
Profit before tax		**1,282.29**	1,162.55
Adjustment to reconcile profit before tax to net cash flows:			
Depreciation and amortisation		**201.78**	186.76
Foreign exchange differences (gain)/loss (net)		**(14.61)**	2.16
Loss/(Gain) on disposal of property, plant and equipment (net)		**7.94**	(3.84)
Guarantee Commission		**(0.37)**	(8.98)
Finance Cost		**105.87**	114.51
Interest income classified as Investing cash flows		**(395.33)**	(220.77)
Share based payment expense		**-**	69.65
Operating profit before working capital changes		**1,187.57**	1,302.04
Movement in Working Capital			
(Increase) in trade and other receivables and prepayments		**(128.24)**	(148.51)
Decrease/(increase) in inventories		**(496.36)**	95.76
Increase in trade payables and other payables		**329.61**	568.06
Increase in provisions		**8.10**	7.88
Cash generated from operations		**900.68**	1,825.23
Income taxes paid (net of refunds)		**(270.36)**	(230.72)
Net cash flows generated from operating activities	**(A)**	**630.32**	1,594.51
Cash Flow from investing activities			
Purchase of Property, plant and equipment including captial work in progress and capital advances		**(176.44)**	(206.31)
Proceeds from sale of property, plant and equipment		**2.96**	12.78
Disposal/Write off of Investments in subsidiaries		**(1.00)**	
Loan to Subsidiaries		**(1,797.18)**	(1,671.88)
Repayment of Loan from Subsidiaries		**1,302.03**	23.40
Fixed deposit / Margin money placed		**(0.25)**	-
Interest received		**395.33**	220.77
Net cash flow used in investing activities	**(B)**	**(274.55)**	(1,621.24)
Cash flow from financing activities			
Proceeds from Fresh issue of Equity shares		**3.04**	-
Securities premium on fresh issue of Equity shares		**1,496.96**	-
Share issue expenses		**(53.15)**	-
Proceeds/(repayment) from short-term borrowings (net)		**(1,569.23)**	(167.89)
Proceeds from long-term borrowings		**67.14**	180.32
Repayment of long-term borrowings		**(80.00)**	(80.00)
Payment of Lease Liabilities		**(4.25)**	(3.97)
Interest paid on Lease liabilities		**(1.04)**	(1.40)
Finance cost excluding (Interest paid on Lease liabilities) paid		**(105.05)**	(114.89)
Net cash flow generated from financing activities	**(C)**	**(245.58)**	(187.83)
Net increase/(decrease) in cash and cash equivalents	**(A+B+C)**	110.19	(214.56)
Cash and cash equivalents at the beginning of the period		**50.39**	225.13
Cash and cash equivalents at the end of the period		**160.58**	10.57

Symbiotec Pharmalab Limited

Corporate Identity Number (CIN):U24232MP2002PLC015293

Regd. Office:385/2, Pigdamber, Rau, Mhow,Indore – 453331, Madhya Pradesh, India

Email: investorrelations@symbiotec.com Website: https://symbiotec.com

Statement of unaudited standalone financial results for the quarter ended and half year ended September 30,2026

Notes:

1. The Unaudited Standalone Financial Results ("Statements") for the quarter ended and half year ended on September 30, 2026, has been reviewed by the Audit Committee and thereafter approved by the Board of Directors of the Symbiotec Pharmalab Limited ("Company") at its meeting held on November 5, 2026. The statutory auditors have carried out a limited review of these Statements and issued unmodified report thereon.

2. These Statements has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, (Ind AS 34) Interim Financial Reporting prescribed under section 133 of Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

3. The Unaudited Standalone financial results for the quarter ended and half year ended September 30, 2025, are presented based on the information compiled by management of the Company and have not been subjected to review or audit by the statutory auditors. However, the management has prepared the results for the said period applying consistent accounting policies and has exercised necessary due diligence to ensure the said figures provide a true and fair view of the Company's affairs.

4. The figures of the quarter ended June 30, 2026, have been extracted from the unaudited financial results of the Company and the figures for the year ended March 31, 2026, have been extracted from the audited financial statements of the Company.

5. During the quarter ended September 30, 2026, the Company had completed its Initial Public Offering ("IPO") of 1,77,86,442 nos. of equity shares of face value of Rs. 2 each at an issue price of Rs. 988 per share (including a share premium of Rs. 986 per share). A discount of Rs. 90 was offered to eligible employees bidding in the employee's reservation portion of 33,407 nos. of equity shares. The issue comprised of 15,21,261 nos. of equity shares offered as fresh issue aggregating to Rs. 1,500.00 million and 1,62,65,181 nos. of equity shares offered as offer for sale by selling shareholders aggregating to Rs. 16,070.00 million. Pursuant to IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited ("NSE") and BSE Limited ("BSE") on September 1, 2026.

   Consequent to allotment of fresh issue, the paid up equity share capital of the Company has increased from Rs. 125.47 million consisting of 62,734,851 equity shares of Rs. 2 each to Rs. 128.51 million consisting of 64,256,112 equity shares of Rs. 2 each.

   The Company received net proceeds of Rs. 1,420.25 million (net of IPO expenses of Rs. 79.75 million). The utilisation of net proceeds is summarised below:

Symbiotec Pharmalab Limited

Corporate Identity Number (CIN):U24232MP2002PLC015293

Regd. Office:385/2, Pigdamber, Rau, Mhow,Indore – 453331, Madhya Pradesh, India

Email: investorrelations@symbiotec.com Website: https://symbiotec.com

Statement of unaudited standalone financial results for the quarter ended and half year ended September 30,2026

(Amount in Rs. millions)

Particulars	Net proceeds to be utilised as per prospectus	Utilisation of net proceeds upto September 30, 2026	Unutilised net proceeds upto September 30, 2026
Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by our Company	1125.25	1125.00	0.25**
General corporate purposes	295.00	295.00*	-
Total	**1,420.25**	**1,420.00**	**0.25**

*Comprises of certain borrowings prepaid/repaid of Rs. 295 million from the general corporate purposes pool.
**Out of the net IPO proceeds which were unutilised as at September 30, 2026, Rs. 0.25 million is held in Monitoring account.

6. The Company's business segment consists of a single segment of "Manufacturing and Selling of Pharmaceuticals products and services" as per the requirement of Indian Accounting Standard (Ind AS) 108 "Operating Segment". Accordingly, no separate segment information is provided.

7. Exceptional items for the year ended March 31, 2026 includes:

Particulars	Year ended
	March 31, 2026 (Audited)
Impact of new wage code on gratuity and leave encashment	83.21
Provision for Impairment of investment and loans in/given to subsidiary	528.13
Total	611.34

8. These unaudited standalone financial results of the Company for the quarter ended and half year ended September 30, 2026, are available on the BSE Limited website (URL: www.bseindia.com), National Stock Exchange of India Limited (URL: www.nseindia.com), and on the Company's website (URL: www.symbiotec.com).

For and on behalf of the Board of Directors of

Symbiotec Pharmalab Limited

CIN : U24232MP2002PLC015293

ANIL SATWANI

Digitally signed by ANIL SATWANI
Date: 2026.11.05 18:58:36 +05'30'

Anil Satwani
Managing Director
Place: Indore
Date: November 05,2026